Recent Updates
Recently added Catalysts
Specialist biotech fund · SEC 13F

Tang Capital Management 13F Holdings (Q3 2026)

According to its SEC 13F filed on Nov 16, 2026, Tang Capital Management reported 42 long positions worth $2.16B as of Sep 30, 2026. AUPH is 9.7% of the portfolio and the top 10 holdings are 64%. Against Q2 2026 it opened 5 new positions, added to 11, trimmed 0 and exited 1. 7 holdings have a dated FDA decision or data readout in the next 90 days, and 11 more expect one in a stated window such as "H2 2026".

Data as of Sep 30, 2026SEC 13F filed Nov 16, 2026Next filing (Q4 2026) due Feb 16, 2027Value as filed; options at underlying sharesLong positions only
Market Value$ 2.17 B13F value, as filed
QoQ Changes-1.27 %13F value vs the previous quarter
Holdings45 42 stocks · 0 option positions
PeriodQ3 202613F reporting quarter
Holdings in Top 20 % top 10: 64% of the portfolio
Activity vs Q2 20265 new11 added · 0 trimmed · 1 exits
Catalysts ahead7dated in 90 days · +11 in a stated window

Catalysts ahead in this portfolio

Dated FDA decisions and data readouts for its holdings in the next 90 days, with our probability of approval

Nov 18, 2026PMVPPhase 2 data presentation: Rezatapopt (PC14586)PoA 32%
Dec 12, 2026LEGNPhase 3 data presentation: CARVYKTI (ciltacabtagene autoleucel; cilta-cel)PoA 99%

5 more with a subscription

What changed vs Q2 2026

ARDXArdelyx$31M
VERAVera Therapeutics, Inc.$16M

Full lists with a subscription

Portfolio over time

13F value by quarter, Q1 2021 to Q3 2026

Q1 2021: $355MQ3 2026: $2.17B

By company stage (share of value)

Commercial 65%Clinical 29%Other 5%

Holdings

Every position in the 13F, with the change since the fund's previous filing, how many of the 45 specialist funds also own it, and its next FDA catalyst. Option positions are labelled CALL or PUT.

Showing 6 Stocks Out Of 45. Click On The Tickers For More Details
Stock Company Name Shares Held Market Value % of Portfolio QoQ Change Position Change Also Held By Stage Next Catalyst
MRNA
MRNA
MODERNA INC
50.00 K
9.63 M
0.4
Unchanged
Commercial
Dec 12, 2026
Phase 1/2 data presentation
VRDN
VRDN
VIRIDIAN THERAPEUTICS INC
1.79 M
36.91 M
1.7
Unchanged
Commercial
Expected Q4 2026
IND Submission
LKFT
LKFT
LAKEFRONT BIOTHERAPEUTICS NV
3.99 M
118.18 M
5.4
New
Clinical
Dec 13, 2026
Phase 1b data presentation
KNSA
KNSA
KINIKSA PHARMACEUTICALS INTL
2.26 M
168.61 M
7.8
Unchanged
Commercial
None in 90 days
TARS
TARS
TARSUS PHARMACEUTICALS INC
1.92 M
150.75 M
6.9
Added +22%
Commercial
None in 90 days
NVCT
NVCT
NUVECTIS PHARMA INC
1.58 M
33.33 M
1.5
Added +2%
Clinical
Expected Q4 2026
IND Submission

Top 20 Holdings

Size = share of the portfolio. Option positions show CALL or PUT.

Who else owns these stocks?

All Stock Holdings ranks every biotech stock by how many of the 45 specialist funds own it, and whether that number rose or fell this quarter. Click "of 45 funds" on any row above, or open the full view.

Open All Stock Holdings ›

Questions about Tang Capital Management's 13F

What does Tang Capital Management own?

42 stocks worth $2.16B at Sep 30, 2026, as reported in its 13F, led by AUPH (9.7% of the portfolio). The full list is in the Holdings table above.

What did it buy and sell last quarter?

Against Q2 2026: 5 new positions, 11 increases, 0 reductions and 1 full exits, from its 13F filings.

How current is this data?

13F filings are due 45 days after each quarter ends, so they show positions at quarter end, not today. The next filing (Q4 2026) is due Feb 16, 2027.

Why are some positions labelled CALL or PUT?

Those are option positions (calls and puts). The 13F reports them as the shares underlying the option, with no strike or expiry, so they are listed apart from share positions.

Source: SEC EDGAR Form 13F-HR filed by TANG CAPITAL MANAGEMENT LLC, accession 0001214659-26-014410, filed Nov 16, 2026. Values as filed; option positions are shown at the value of the underlying shares and labelled CALL or PUT.